Realistic overtake price, page-57

I didn't include that as the 4C clearly states that "The external party is undertaking due diligence however no binding offer has been made and there is no guarantee that a transaction will eventuate."  If it does Admedus will get whatever they get for it but it will reduce quarterly cashflow by $3.5M according to the last 4C.  Of course costs will also go down, but I've no idea what % of overall operational cost is attributable to the infusions business.  This is of course important because the cost structure will determine what the business is worth to the potential buyer.  Anyway, I'm not trying to "down ramp" - I mean no offence to anyone...just my take on where things are at.